Investigational drug · Phase 2
SSGJ-613
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gout Arthritis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "SSGJ-613"
First trial start
2026
Aug 2, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SSGJ-613", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gout Arthritis
Approved drugs for the same conditions: Gout
Largest trials
Live from ClinicalTrials.gov: studies naming "SSGJ-613" as an intervention, largest first.
- A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute GoutPivotal-lookingStatus unknown
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
NCT06169891 · 500 participants (planned) · Start Dec 2023 · Primary completion Dec 2024
Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg; Compound Betamethasone Injection · For: Acute Gout
- A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering TreatmentPivotal-lookingNot yet recruiting
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
NCT07708181 · 200 participants (planned) · Start Aug 2, 2026 · Primary completion Aug 11, 2027
Drug: SSGJ-613 100 mg Q12W; SSGJ-613 200 mg Q12W and 2 more · For: Gout Arthritis
- A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.Pivotal-lookingStatus unknown
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
NCT06270225 · 157 participants · Start Mar 30, 2024 · Primary completion Oct 2024
Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg; Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg and 1 more · For: Gout Arthritis
Sites: Shanghai, China
- A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute GoutPivotal-lookingStatus unknown
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
NCT05588908 · 120 participants (planned) · Start Jun 29, 2022 · Primary completion Sep 2023
Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib); Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib) and 4 more · For: Acute Gout
Sites: Wuhan, China; Linyi, China; Shanghai, China
- The MAD Study of SSGJ-613 in Healthy SubjectsStatus unknown
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
NCT05966701 · 36 participants (planned) · Start Aug 10, 2023 · Primary completion Mar 10, 2024
Drug: SSGJ-613; Placebo · For: Arthritis, Gouty
Sites: Shanghai, China
- Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody InjectionStatus unknown
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
NCT05027373 · 34 participants (planned) · Start Aug 13, 2021 · Primary completion Apr 30, 2022
Drug: SSGJ-613; Placebo · For: Systemic Juvenile Idiopathic Arthritis; Periodic Fever Syndrome
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- SSGJ-613 Alleviates Pain and Reduces the Risk of Acute Flares in Patients With Gout: A Randomized, Double-Blind, Phase II Study.
Xue Y, Zhu X, Zhang B, et al. · Int J Rheum Dis 2026
Also in development for Gout Arthritis
- EtoricoxibPhase 34 trials
Laboratorios Silanes S.A. de C.V. · Gout Arthritis, Gout Attack, Acute Low-back Pain
- Etoricoxib fixed doseEtoriPhase 32 trials
Laboratorios Silanes S.A. de C.V. · Gout Arthritis, Gout Attack, Acute Low-back Pain
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.